Does infusion therapy (with ocrelizumab or natalizumab) reduce fatigue in patients with multiple sclerosis?

Does infusion therapy (with ocrelizumab or natalizumab) reduce fatigue in patients with multiple sclerosis? - Fatiguereduktion Ocrevus

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00039175

Enrollment

Registered

2026-02-02

Start date

2025-10-01

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

relapsing remitting and secondary chronic Multiple sclerosis patients

Interventions

Group 1: MS patients who come to the Klinikum Bremen-Ost for ocrelizumab infusion are admitted. After consent, the fatigue niceau is recorded five times: immediately before the next upcoming infusion,

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: able to give consens

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Syndromic fatigue experience recorded by questionnaire.	—

Secondary

Measure	Time frame
Changes in depression, anxiety symptoms, independence of instrumental activity in everyday life.	—

Countries

Germany

Contacts

Public ContactHelmut Hildebrandt

Klinikum Bremen-Ost

helmut.hildebrandt@uni-oldenburg.de+4942140861542

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026